A historic milestone in pandemic preparedness arrived this week as the U.S. Food and Drug Administration granted approval to XOCOVA® (ensitrelvir) — the world’s first oral antiviral cleared for post-exposure prevention of COVID-19. Developed by Osaka-based Shionogi & Co., Ltd., the drug addresses a critical therapeutic void: a clinically proven, convenient option for individuals exposed to the virus before infection takes hold.
Clearance rests on the landmark SCORPIO-PEP Phase 3 trial, where XOCOVA slashed the likelihood of developing symptomatic COVID-19 by 67% versus placebo among household contacts of confirmed cases — regardless of prior vaccination or immunity status. The simple five-day oral regimen produced no reports of taste disturbance, a side-effect frequently cited with rival antivirals.
The public health stakes are considerable. CDC surveillance estimates up to 12.4 million new U.S. COVID-19 cases between October 2025 and May 2026, with hospitalisations reaching 240,000. XOCOVA’s approval — coming 15 days ahead of its PDUFA deadline — signals strong regulatory confidence. As COVID-19 transitions from pandemic emergency to endemic reality, this novel prophylactic redefines how healthcare systems and individuals respond to exposure.
Written By: Sayan Das
Graphics by: Pramit Hazra
